false0001811115true00-0000000Ordinary shares, nominal value £0.0025 per shareAmerican Depositary Shares, each representing two ordinary shares, nominal value £0.0025 per share00018111152023-10-312023-10-310001811115rnlx:AmericanDepositarySharesMember2023-10-312023-10-31

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 31, 2023

 

Renalytix plc

(Exact name of registrant as specified in its Charter)

 

England and Wales

001-39387

Not Applicable

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

Finsgate

5-7 Cranwood Street

London EC1V 9EE

United Kingdom

(Address of principal executive offices) (Zip Code)

 

+44 20 3139 2910
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading
Symbol(s)

Name of each exchange
on which registered

Ordinary shares, nominal value £0.0025 per share

n/a

The Nasdaq Stock Market LLC*

American Depositary Shares, each representing two ordinary shares, nominal value £0.0025 per share

RNLX

The Nasdaq Stock Market LLC

 

 

 

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01. Regulation FD Disclosure

On October 30, 2023, Renalytix plc (the “Company”) issued a press release announcing that the Company’s Annual General Meeting (“AGM”) will be held in-person on December 15, 2023 at 15:30 p.m. (GMT) at 6 Stratton Street, Mayfair, London W1J 8LD.

In addition, the Company’s Annual Report for the year ended June 30, 2023 has been published on the Company’s website. The Annual Report will be posted to shareholders who have not consented to receive electronic communications.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated October 30, 2023

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

renalytix plc

 

 

 

Dated: October 31, 2023

By:

/s/ James McCullough

 

 

James McCullough
Chief Executive Officer

 

 

img102423453_0.jpg 

Exhibit 99.1

 

Renalytix plc

(“Renalytix” or the “Company”)

 

Announcement of AGM and

Publication of Annual Report 2023

 

LONDON and SALT LAKE CITY, UT October 30, 2023 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Annual General Meeting (“AGM”) will be held in-person on 15 December 2023 at 15.30 p.m. (GMT) at 6 Stratton Street Mayfair, London W1J 8LD.

 

In addition, the Company’s Annual Report for the year ended 30 June 2023 has now been published on the Company’s website: https://investors.renalytix.com/financials-and-filings/annual-and-half-year-reports

 

The 2023 Annual Report will be posted to shareholders who have not consented to receive electronic communications.

 

To help with practical arrangements for the AGM, any Shareholder wishing to attend is requested to register first by contacting Walbrook PR via email at renalytix@walbrookpr.com or by telephone at +44 (0)20 7933 8790.

 

For further information, please contact:

 

Renalytix plc

www.renalytix.com

James McCullough, CEO

Via Walbrook PR

 

 

Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

 

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Shalin Bhamra

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Alice Woodings

Mob: 07980 541 893 / 07407 804 654

 

CapComm Partners

 

Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

 

v3.23.3
Document And Entity Information
Oct. 31, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 31, 2023
Entity Registrant Name Renalytix plc
Entity Central Index Key 0001811115
Securities Act File Number 001-39387
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One Finsgate
Entity Address, Address Line Two 5-7 Cranwood Street
Entity Address, City or Town London
Entity Address, Country GB
Entity Address, Postal Zip Code EC1V 9EE
City Area Code +44
Local Phone Number 20 3139 2910
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary shares, nominal value £0.0025 per share
No Trading Symbol Flag true
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
American Depositary Shares [Member]  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares, each representing two ordinary shares, nominal value £0.0025 per share
Trading Symbol RNLX
Security Exchange Name NASDAQ
Renalytix (PK) (USOTC:RTNXF)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Renalytix (PK).
Renalytix (PK) (USOTC:RTNXF)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Renalytix (PK).